President of the Chulabhorn Research Institute Presented with an Honorary Doctorate of Philosophy in Chemistry from Mahidol University

Under Her Royal Initiative, a Pharmaceutical Manufacturing Facility was established under the Chulabhorn Royal Academy.  It is the first facility in Thailand to produce drugs for cancer treatment.  It is also accredited to the international GMP PIC/S standard, which will reduce the costs of importing drugs and increase opportunities for people to have equal and sustainable access to quality drugs for cancer treatment across the board.  Her Royal Highness decided on the production of targeted cancer therapies, highly effective drugs that can be used to treat various types of cancer, including Thailand’s first domestically produced targeted cancer therapy under the name “IMCRANIB 100”.

Furthermore, the President of the CRI is committed to laying the foundation for the “Ecosystem of Biologics Development”, resulting in the establishment of the “Center for Biologics Research and Development (CBRD)”, CRI, to support comprehensive processes of research, development, and production of biologics.  This has led to the successful development of a “trastuzumab” biosimilar, a targeted cancer therapy used to treat various types of cancer, especially breast cancer.  It is considered one of the innovations representing advances in current cancer treatment.  It was also granted a drug registration license by the Food and Drug Administration, Ministry of Public Health, under the name “HERDARA”, graciously bestowed by Her Royal Highness Herself.

In addition, during the outbreak of the COVID-19, the President of the CRI conducted research with researchers at the CRI and succeeded in synthesizing the Molnupiravir within six months.  Her Royal Highness graciously bestowed the technology on the government to scale up for industrial production, benefiting people across the nation.